- First-line treatments are calcium channel blockers (Ia, A) and angiotensin II receptor antagonists (Ib, C).
- Other treatments that may be considered are: selective serotonin reuptake inhibitors, α-blockers and statin therapy (III, C).
- Phosphodiesterase type 5 inhibitors are being used increasingly for SSc-related RP (IIa, C).
- Intravenous prostanoid (e.g. iloprost; Ia, B) and digital (palmar) sympathectomy (with or without botulinum toxin injection) should be considered in severe and/or refractory cases (III, D).
- DUs require integrated management by a multidisciplinary team; management includes local and systemic treatment (III, C).
- Oral vasodilator treatment should be optimized, analgesia optimized and any infection promptly treated (III, C).
- Sildenafil should now be used before considering i.v. prostanoids and bosentan, in line with the current National Health Service (NHS) England Clinical Commissioning policy  (I, A).
- In severe active digital ulceration, patients should receive i.v. prostanoid (Ia, B). In patients with recurrent, refractory DUs, a phosphodiesterase type 5 inhibitor (IIa, B) or i.v. prostanoid (Ia, B) and an endothelin receptor antagonist (including bosentan; Ia, B) should be considered.
- Digital (palmar) sympathectomy (with or without botulinum toxin injection) may also be considered in severe and/or refractory cases (III, D).
BSR and BHPR guideline for the treatment of systemic sclerosis
To view the UK treatment guidelines for Raynaud’s Phenomenon, Click here
All of your monies will be used for medical research purposes only, lead by the world trail blazer Dr Kevin Howell.
|Dr Howell and I, Sept 2017|
Facebook Page: Raynauds Unit Royal Free Hospital
To read my articles:
Rare Disease Day 2018, Research - Taking Part in Clinical Trials, Click here
March Autoimmune Disease Awareness Month 2018, Click here
Global patient video, Click here
Becoming a Patient Research Ambassador for the NIHR, Click here
If we only had more RESEARCH investment for Scleroderma, Raynaud's, Autoimmune Rare Disease, Click here
The Importance of Medical Research and Awareness to the Scleroderma, Raynaud's, Autoimmune Rare Disease patient, Click here
Expert Specialist Centres, Click here
World Scleroderma Day 29th June 2016, Click here
World Scleroderma Day 29th June 2017, Click here
Why Global Collaboration is important to the Rare Disease Patient, Click here
2016 Rare Disease Day Patient Voice